622 related articles for article (PubMed ID: 22265698)
1. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
2. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
5. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; Andersen J; Paridaens R; van de Velde CJ; Lønning PE; Morden J; Reise J; Cisar L; Menschik T; Coombes RC
J Clin Oncol; 2012 Mar; 30(7):709-17. PubMed ID: 22042946
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
van de Velde CJ; Rea D; Seynaeve C; Putter H; Hasenburg A; Vannetzel JM; Paridaens R; Markopoulos C; Hozumi Y; Hille ET; Kieback DG; Asmar L; Smeets J; Nortier JW; Hadji P; Bartlett JM; Jones SE
Lancet; 2011 Jan; 377(9762):321-31. PubMed ID: 21247627
[TBL] [Abstract][Full Text] [Related]
8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
9. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
[TBL] [Abstract][Full Text] [Related]
10. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors and musculoskeletal adverse events.
Liedke PE; Goss PE
Lancet Oncol; 2012 Apr; 13(4):333-4. PubMed ID: 22265696
[No Abstract] [Full Text] [Related]
12. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
14. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
[TBL] [Abstract][Full Text] [Related]
17. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
[TBL] [Abstract][Full Text] [Related]
18. Exemestane for breast-cancer prevention in postmenopausal women.
Goss PE; Ingle JN; Alés-Martínez JE; Cheung AM; Chlebowski RT; Wactawski-Wende J; McTiernan A; Robbins J; Johnson KC; Martin LW; Winquist E; Sarto GE; Garber JE; Fabian CJ; Pujol P; Maunsell E; Farmer P; Gelmon KA; Tu D; Richardson H;
N Engl J Med; 2011 Jun; 364(25):2381-91. PubMed ID: 21639806
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]